To determine whether ICB therapy reactivates CD39+PD-1+ Tex cells in ESCC patients, we examined changes in circulating immune dynamics before and after ICB therapy within the same research cohort (Figs. 1a, 7a–d). The gene discussed is ENTPD1; the disease is esophageal squamous cell carcinoma.